About
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 118 investors are based in Suzhou, Jiangsu, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- Suzhou, China
Contact Information
Find more investors like Innovent
Search Investors